Key Highlights
- ImmuPharma Plc (LSE:IMM) is shown up 15.44% on 28 September 2026, placing the specialist healthcare company among the strongest risers in the session.
- Investor attention is centred on the company's lead P140 programme, its international Patent strategy and potential commercial partnering.
- ImmuPharma has continued discussions with its US licensing partner regarding P140 and has stated that commercial partnering remains a major objective for 2026.
- The company recently filed an international patent application covering its P140 precision-medicine approach and the identification of patients with a specific Type M immune profile.
- New peer-reviewed research has also expanded the potential scientific applications being investigated for P140 beyond its original autoimmune focus.
- Kapiglucagon has moved from development planning toward active execution, with regulatory, Manufacturing and bioanalytical work now underway.
Why Is ImmuPharma Plc in Focus Today?
ImmuPharma has recorded a 15.44% gain on 28 September 2026, bringing renewed attention to LSE:IMM.
The company operates in the biotechnology and drug-development space, meaning share-price movements can be particularly sensitive to clinical, regulatory, intellectual-property and partnering developments.
The latest rally comes after a series of developments surrounding the company's two principal programmes: P140 and Kapiglucagon.
P140 remains the central asset and is being developed for autoimmune and inflammatory diseases. Kapiglucagon represents a separate development opportunity and has moved into a more active development phase.
For investors, the key question is whether these programmes can generate meaningful commercial or clinical milestones over the coming periods.
Why Is P140 So Important for LSE:IMM?
P140 remains ImmuPharma's principal development and partnering priority.
The company describes P140 as a peptide-based therapeutic candidate designed to address immune dysfunction in autoimmune disease.
A particularly important recent development has been the company's move toward a precision-medicine approach, using the Type M immune profile to identify patients who may have a greater likelihood of responding to P140.
ImmuPharma has filed an international patent application covering this approach, extending the intellectual-property strategy beyond its earlier UK filing.
For investors, intellectual-property protection is important because successful patent development can potentially strengthen the commercial position of a pharmaceutical programme.
However, patent progress does not by itself establish clinical efficacy or commercial success.
Could New P140 Research Broaden the Opportunity?
Another reason ImmuPharma is attracting attention is the growing body of research around P140.
Recent research has examined P140 in areas beyond its original lupus-focused development programme.
Research from the University of Murcia investigated P140 in relation to glioblastoma, while more recent work involving CNRS and the University of Strasbourg examined P140 activity in a preclinical model of metabolic dysfunction-associated steatohepatitis.
These findings potentially broaden the scientific interest surrounding P140, although the company's primary development focus remains autoimmune disease.
For LSE:IMM, investors will be watching whether additional scientific research eventually translates into new development programmes, partnerships or commercial opportunities.
Why Is Commercial Partnering Important?
Commercial partnering remains one of the most important potential catalysts for ImmuPharma.
The company has said discussions with its US licensing partner have been constructive and that it is seeking a value-enhancing commercial deal for P140 during 2026.
A meaningful Partnership could potentially provide funding, development expertise or commercial infrastructure.
At the same time, investors need to distinguish between ongoing discussions and an executed commercial agreement. Until a transaction is formally completed, its financial terms and strategic impact remain uncertain.
What Is Happening With Kapiglucagon?
Kapiglucagon is another important part of the ImmuPharma story.
During 2026, the company completed its overall development plan and moved the programme from development planning into active execution.
Regulatory activities, API manufacturing, drug-product development and bioanalytical work have been initiated.
This gives ImmuPharma a second development programme that could become increasingly important to the company's longer-term pipeline.
The key areas investors will monitor include development milestones, regulatory progress, manufacturing activities and the funding required to advance the programme.
What Do ImmuPharma's Financials Show?
ImmuPharma remains a development-stage company, so profitability and cash resources are important considerations.
For the six months ended 30 June 2026, the company reported an operating loss of approximately £1.1 million, compared with £1.2 million a year earlier.
Research and development expenditure was approximately £0.6 million, while administrative expenses were around £0.4 million.
The company reported a larger overall loss of approximately £4.7 million, partly because of a fair-value finance loss associated with a derivative financial asset.
Cash at the end of June stood at approximately £0.7 million.
This makes future financing, partnering and development funding important issues for investors to monitor.
What Are Investors Watching After the 15.44% Rise?
Following the sharp move in LSE:IMM, the main areas of attention include:
- P140 development progress.
- Lupus-related development milestones.
- Type M precision-medicine research.
- International patent progress.
- Commercial partnering discussions.
- Potential licensing arrangements.
- Kapiglucagon development.
- Regulatory milestones.
- Manufacturing progress.
- Research and development spending.
- Cash resources.
- Potential future funding requirements.
- Additional scientific publications.
- New applications for P140.
Could LSE:IMM Remain Volatile?
Biotechnology stocks can experience substantial share-price Volatility because their valuations are often linked to future clinical, regulatory and commercial milestones rather than current earnings.
ImmuPharma's 15.44% gain on 28 September 2026 therefore puts the company firmly in focus, but the sustainability of the move will depend on whether upcoming developments provide measurable progress across its pipeline.
The most important potential catalysts remain P140 partnering, intellectual-property developments, scientific data and the advancement of Kapiglucagon.
What Could Drive ImmuPharma Plc Going Forward?
The next phase of the LSE:IMM story is likely to be shaped by the company's ability to convert scientific and intellectual-property progress into commercial and development milestones.
A successful P140 partnership could materially change the company's funding and commercial position. Continued patent progress could strengthen the protection surrounding its precision-medicine strategy. Further Kapiglucagon development could broaden the pipeline.
At the same time, investors will need to watch cash requirements, development expenditure and the timing of future milestones.
The 15.44% rise on 28 September 2026 has therefore placed ImmuPharma back into focus, with P140, partnering, patents and Kapiglucagon representing the principal areas to watch.






Please wait processing your request...